Cherrie Galletly1. 1. Discipline of Psychiatry, School of Medicine, University of Adelaide, Suite 13, The Adelaide Clinic Consulting Suites, 33 Park Tce Gilberton, Adelaide, South Australia 5081, Australia. cherrie.galletly@adelaide.edu.au
Abstract
INTRODUCTION: Schizophrenia is often associated with chronic disability and poor outcome. In addition to positive symptoms, such as hallucinations and delusions, and negative symptoms including poverty of speech and blunted affect, schizophrenia is also associated with deficits in cognitive function. It has been increasingly recognized that the severity of cognitive impairment is a major determinant of outcome. Therefore, interventions to improve cognitive function also have the capacity to improve quality of life and social and occupational outcomes. Whilst some of the antipsychotic drugs have shown some selective benefits, there is some controversy about the extent of these benefits. OBJECTIVES: This article provides an overview of research into drugs that might enhance cognition in schizophrenia. CONCLUSION: Drugs such as modafanil and galantamine are being evaluated, and a number of new drugs are currently in development. Standardized cognitive assessment measures are being developed so studies can be compared more easily. This field is advancing rapidly, but as yet, no widely applicable, evidence-based treatments are available to the clinician.
INTRODUCTION:Schizophrenia is often associated with chronic disability and poor outcome. In addition to positive symptoms, such as hallucinations and delusions, and negative symptoms including poverty of speech and blunted affect, schizophrenia is also associated with deficits in cognitive function. It has been increasingly recognized that the severity of cognitive impairment is a major determinant of outcome. Therefore, interventions to improve cognitive function also have the capacity to improve quality of life and social and occupational outcomes. Whilst some of the antipsychotic drugs have shown some selective benefits, there is some controversy about the extent of these benefits. OBJECTIVES: This article provides an overview of research into drugs that might enhance cognition in schizophrenia. CONCLUSION: Drugs such as modafanil and galantamine are being evaluated, and a number of new drugs are currently in development. Standardized cognitive assessment measures are being developed so studies can be compared more easily. This field is advancing rapidly, but as yet, no widely applicable, evidence-based treatments are available to the clinician.
Authors: Robert E Kelly; Lisa J Cohen; Randye J Semple; Philip Bialer; Adam Lau; Alison Bodenheimer; Elana Neustadter; Arkady Barenboim; Igor I Galynker Journal: Psychol Med Date: 2006-08-08 Impact factor: 7.723
Authors: C A Briggs; D J Anderson; J D Brioni; J J Buccafusco; M J Buckley; J E Campbell; M W Decker; D Donnelly-Roberts; R L Elliott; M Gopalakrishnan; M W Holladay; Y H Hui; W J Jackson; D J Kim; K C Marsh; A O'Neill; M A Prendergast; K B Ryther; J P Sullivan; S P Arneric Journal: Pharmacol Biochem Behav Date: 1997 May-Jun Impact factor: 3.533
Authors: Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton Journal: Schizophr Res Date: 2004-12-15 Impact factor: 4.939
Authors: Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman Journal: Arch Gen Psychiatry Date: 2003-02
Authors: Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten Journal: Schizophr Bull Date: 2013-04-15 Impact factor: 9.306
Authors: Andrew M McIntosh; Arthur A Simen; Kathryn L Evans; Jeremy Hall; Donald J Macintyre; Douglas Blackwood; Andrew D Morris; Blair H Smith; Anna Dominiczak; David Porteous; Hb Ian J Deary; Pippa A Thomson Journal: Front Genet Date: 2012-07-02 Impact factor: 4.599
Authors: Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort Journal: Front Psychiatry Date: 2013-12-04 Impact factor: 4.157
Authors: Davy Vancampfort; Brendon Stubbs; Marc De Hert; Christy du Plessis; Caleb Ademola Omuwa Gbiri; Jepkemoi Kibet; Nancy Wanyonyi; James Mugisha Journal: Pan Afr Med J Date: 2017-02-28
Authors: Linda J Bristow; Amy E Easton; Yu-Wen Li; Digavalli V Sivarao; Regina Lidge; Kelli M Jones; Debra Post-Munson; Christopher Daly; Nicholas J Lodge; Lizbeth Gallagher; Thaddeus Molski; Richard Pieschl; Ping Chen; Adam Hendricson; Ryan Westphal; James Cook; Christiana Iwuagwu; Daniel Morgan; Yulia Benitex; Dalton King; John E Macor; Robert Zaczek; Richard Olson Journal: PLoS One Date: 2016-07-28 Impact factor: 3.240